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The European Union and the United Kingdom currently risk being victims of their
own vaccine nationalism. The time pressure for securing as many vaccine doses
against COVID-19 as possible has led to hiccups and even tensions between both.
At the heart of the matter is AstraZeneca’s delay in distributing a given number of
doses in the European Union. Meanwhile, it continues to serve the United Kingdom
in a timely fashion. 
In a speech of 26 January 2021, European Commission President von der
Leyen announced the possibility of implementing a “vaccine export transparency
mechanism”. Though the details are not yet particularly clear, the aim of this
mechanism would be to undertake a stricter monitoring of how many vaccine exports
are being made from the European Union. The threat of imposing export restrictions,
including to the United Kingdom, is now on the table.
The scenario above sheds light on the consequences of the “me-first” logic
underlying vaccine nationalism. As we have argued elsewhere, avoiding this was an
objective of the global alternative for COVID-19 vaccines procurement, the COVAX
Initiative, developed mainly by the World Health Organization (WHO), the public-
private-partnership Gavi (the Vaccines Alliance) and the Norwegian NGO Coalition
for Epidemic Preparedness and Innovation (CEPI). We argue that by opting for the
bilateral instead of the global and multilateral approach, the European Union and the
United Kingdom now witness a face-off of their own creation, while endangering the
effective distribution of a life-saving medicine.
A Bilateral vs a Multilateral Approach to Vaccine
Procurement
At the core of the United Kingdom’s and the European Union’s vaccine procurement
strategy are Advance Purchase Agreements (APAs), addressed at length here.
These consist of bilateral contracts struck between a pharmaceutical developer,
on one hand, and a potential buyer – whether public institutions or also private
actors – on the other hand with a commitment for an unfinished product. The
buyer undertakes to purchase a certain amount of doses at a negotiated price, as
well as providing financial guarantees beforehand in case they do not. In return,
pharmaceutical companies commit to provide that amount of the projected vaccine
once authorized for use by a regulatory agency – in the case of the European Union,
the European Medicines Agency. Due to uncertainties related to the vaccines’
research development process, these commitments entail a degree of risk. However,
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the vaccine developed and produced by AstraZeneca jointly with Oxford University
has already received regulatory authorization by the EMA.
Although the question of “how much” doses have been purchased is not disputed,
the one of “when” exactly a pharmaceutical company has to deliver the vaccine is
currently in the eye of the storm. The European Union and AstraZeneca have had
a public fall-out over the respective duties in their bilateral APA. On 25 January
2021, after a series of discussions with the pharmaceutical company, the President
of the European Commission, Ursula von der Leyen, expressed her dismay at the
company’s announced delays in the delivery of the amount of doses promised back
in 2020.
This is exactly the situation that securing the vaccine through COVAX would have
avoided. Indeed, while now the general impression is that COVAX has been set up
for low-income countries (“financed states”), it was actually designed to allow every
state to secure doses through it, i.e. a truly multilateral and global approach. Higher
income states can join as “self-financing participants”. For that purpose, they sign a
standard legal agreement with Gavi, the Vaccines Alliance, the legal administrator
of COVAX. In turn, Gavi signs contracts with pharmaceutical companies, similar to
what the European Commission does. In the first phase of distribution, all countries
participating in COVAX receive doses for up to 20% of their population, with the
option for self-financing parties to secure more afterwards.
Since Gavi signs only a single agreement with each pharmaceutical company, this
prevents states from outbuying each other to get better deals, i.e. faster deliveries. It
also guarantees a standard price for everyone – a matter which last December led to
controversy, since some states, such as the United States, paid more than others for
the same product through their bilateral APAs.
Furthermore, COVAX offers more transparency than bilateral APAs. Through their
agreements with Gavi, self-financing states can know the terms and conditions
of every other vaccine-receiving state at the outset, since the model agreements
are publicly available. Conversely, bilateral APAs between states or the EU and
pharmaceutical companies often include non-disclosure clauses, as reported in
detail here. Matters such as potential liability for failing to fulfill contractual obligations
are often beyond the public eye. There are exceptions, such as the APA between
the European Commission and the German pharmaceutical company CureVac.
However, as bilateral APAs proliferate, states and supranational institutions signing
them usually have no way of knowing whether other states have obtained different,
possibly better terms and conditions. 
The lack of transparency of numerous APAs is currently being put into question.
President von der Leyen claims that the agreements the European Commission
had signed with the company were meant to legally ensure delivery of a determined
volume after regulatory authorization. Conversely, the Chief Executive Officer of
AstraZeneca, Pascal Soriot, claimed that the commitment was not to deliver at a
certain point, but rather a statement of “best efforts”. The European Commission has
published the APA in question. In section 5.1, it states that AstraZeneca “shall use its
Best Reasonable Efforts… to deliver to the Distribution Hubs, following EU marketing
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authorization”, as established in an estimated delivery schedule attached to the
agreement. Whether that provision covers the current delay is an intricate question
of fact and Belgian contract law which governs the APA between AstraZeneca
and the European Union. As regards the question whether AstraZeneca agreed to
different clauses with other countries, this information is not currently in the public
domain.
The delays in delivery might amount to a breach of contract if the company is giving
preference to other countries, while failing to deliver the expected amount of vaccine
doses secured by the European Commission. Conversely, even though the clauses
of contracts in COVAX between Gavi and pharmaceutical companies are not fully
transparent either, at the very least suspicions of preferential treatment to certain
states would have been dispelled thanks to the template agreements.
The Self-Defeating Nature of Vaccine Nationalism
By resorting to bilateral APAs for securing their vaccine doses and not through the
global alternative, delivery of the COVID-19 vaccines is now fueling a bitter standoff
between the United Kingdom and the European Union. Resorting to a multilateral
and global vaccine procurement strategy through COVAX would have avoided the
bitter question of “who is getting it first and on which terms”. It would have prevented
emerging political standoffs that may lead to damaging consequences if stronger
measures, such as export restrictions, are adopted. It shows how the lack of global
solidarity amidst such a decisive moment in curbing the pandemic is a self-defeating
endeavor.
The rampant vaccine nationalism, where states are currently out-buying and leaving
each other behind, is shaping up to be a crisis in itself. Not only is it leaving lower-
income countries behind in the pipeline, but is also pitting higher-income countries
against each other. In times of a catastrophic pandemic, the lack of global solidarity
is not just a matter of moral imperatives – it also happens to be the best means to
avoid a self-defeating competition for the vaccine.
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